Senior Scientist, Bioanalytical Development

About Us

Protagonist Therapeutics is a discovery-through-late-stage development biopharmaceutical company with a proprietary technology platform that enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE™ (icotrokinra), licensed to Johnson & Johnson company Janssen Biotech, Inc., is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor. ICOTYDE was launched in the U.S. in March 2026, is approved for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older and is in Phase 3 development for psoriatic arthritis, ulcerative colitis and Crohn's disease.

ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization. Protagonist also discovered and led development through Phase 3 of rusfertide, a first-in-class hepcidin mimetic peptide licensed to Takeda Pharmaceuticals. An NDA for rusfertide for the treatment of polycythemia vera is under priority review with the FDA.

The Company also has a number of clinical and preclinical programs addressing clinically and commercially validated targets, including an oral IL-17 antagonist peptide, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.

Protagonist Therapeutics is a discovery-through-late-stage development biopharmaceutical company with a proprietary technology platform that enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE™ (icotrokinra), licensed to Johnson & Johnson company Janssen Biotech, Inc., is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor. ICOTYDE was launched in the U.S. in March 2026, is approved for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older and is in Phase 3 development for psoriatic arthritis, ulcerative colitis and Crohn's disease.

ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization. Protagonist also discovered and led development through Phase 3 of rusfertide, a first-in-class hepcidin mimetic peptide licensed to Takeda Pharmaceuticals. An NDA for rusfertide for the treatment of polycythemia vera is under priority review with the FDA.

The Company also has a number of clinical and preclinical programs addressing clinically and commercially validated targets, including an oral IL-17 antagonist peptide, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs. More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at

We are seeking a Senior Scientist in the Bioanalytical department. The qualified candidate will be a critical member of the group and work closely with our established team developing and optimizing analytical methods and performing bioanalytical work to screen chemical entities for new drug candidates. This is an exceptional opportunity to work with a core discovery group within a successful biopharmaceutical company and bring drugs from ideas to the clinic.

• Operate and maintain analytical instrumentation such as HPLC, mass spectrometer, and other lab equipment
• Prepare reagents, calibration standards, QCs and standard curves, and samples for analysis
• Perform, optimize, develop, and execute new and existing analytical methods
• Perform analytical assays (i.e., ELISA) to support PD and efficacy studies
• Work with Bioanalytical team to ensure adequate supplies of consumables and reagents
• Possess technical and scientific understanding of bioanalytical assays and experimental design to support the development
• Keep excellent experimental records
• Effectively communicate results to the Bioanalytical team and cross-functionally
• Follow and maintain laboratory safety protocol and health-conscious environment in the workplace.

• MS in chemistry, analytical chemistry, biochemistry, bioengineering, or related fields with 5+ years of relevant industry or academic experience or BS with 10+ years of experience.
• Previous experience operating and maintaining analytical instrumentation, including HPLC, mass spectrometer,…